Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion

Area of Science:

• Oncolytic virotherapy
• Nerve cancer invasion
• Gene therapy vectors

Background:

• Nerve invasion by cancer cells, particularly pancreatic and head and neck carcinomas, leads to poor patient outcomes.
• Peripheral nerves can facilitate cancer spread to the central nervous system.
• Surgical removal of tumors within nerves causes permanent functional loss and morbidity.

Purpose of the Study:

• To investigate the efficacy of an attenuated herpes simplex virus (HSV), NV1023, as a treatment for cancers with neural invasion.
• To assess the safety and functional impact of NV1023 on peripheral nerve function.
• To evaluate NV1023's oncolytic potential against neurotrophic human carcinoma cell lines.

Main Methods:

• NV1023 was injected into the sciatic nerves of nude mice to assess toxicity and nerve function.
• In vitro cytotoxicity of NV1023 was tested on pancreatic, squamous cell, and adenoid cystic carcinoma cell lines.
• A neural invasion model was created by implanting human carcinoma cells into mouse sciatic nerves, followed by NV1023 treatment.

Main Results:

• NV1023 did not impair nerve function in mice, unlike wild-type HSV-1 which caused paralysis and mortality.
• NV1023 demonstrated significant in vitro cytotoxicity against neurotrophic carcinoma cell lines.
• Mice treated with NV1023 showed significant tumor regression and maintained intact nerve function, contrasting with control groups that developed paralysis.

Conclusions:

• NV1023 oncolytic therapy shows potential for treating cancers involving neural invasion.
• This therapy may effectively preserve neural function in patients with cancer neural invasion.
• These findings suggest significant clinical implications for managing cancers with neural invasion.